Correlation Between Iovance Biotherapeutics and Checkpoint Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Iovance Biotherapeutics and Checkpoint Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Iovance Biotherapeutics and Checkpoint Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Iovance Biotherapeutics and Checkpoint Therapeutics, you can compare the effects of market volatilities on Iovance Biotherapeutics and Checkpoint Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Iovance Biotherapeutics with a short position of Checkpoint Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Iovance Biotherapeutics and Checkpoint Therapeutics.

Diversification Opportunities for Iovance Biotherapeutics and Checkpoint Therapeutics

0.86
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Iovance and Checkpoint is 0.86. Overlapping area represents the amount of risk that can be diversified away by holding Iovance Biotherapeutics and Checkpoint Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Checkpoint Therapeutics and Iovance Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Iovance Biotherapeutics are associated (or correlated) with Checkpoint Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Checkpoint Therapeutics has no effect on the direction of Iovance Biotherapeutics i.e., Iovance Biotherapeutics and Checkpoint Therapeutics go up and down completely randomly.

Pair Corralation between Iovance Biotherapeutics and Checkpoint Therapeutics

Given the investment horizon of 90 days Iovance Biotherapeutics is expected to under-perform the Checkpoint Therapeutics. In addition to that, Iovance Biotherapeutics is 1.01 times more volatile than Checkpoint Therapeutics. It trades about -0.31 of its total potential returns per unit of risk. Checkpoint Therapeutics is currently generating about -0.17 per unit of volatility. If you would invest  317.00  in Checkpoint Therapeutics on December 5, 2024 and sell it today you would lose (60.00) from holding Checkpoint Therapeutics or give up 18.93% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Iovance Biotherapeutics  vs.  Checkpoint Therapeutics

 Performance 
       Timeline  
Iovance Biotherapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Iovance Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Checkpoint Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Checkpoint Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Iovance Biotherapeutics and Checkpoint Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Iovance Biotherapeutics and Checkpoint Therapeutics

The main advantage of trading using opposite Iovance Biotherapeutics and Checkpoint Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Iovance Biotherapeutics position performs unexpectedly, Checkpoint Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Checkpoint Therapeutics will offset losses from the drop in Checkpoint Therapeutics' long position.
The idea behind Iovance Biotherapeutics and Checkpoint Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Complementary Tools

Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories